Breast cancer: Updated guideline recommendations for HER2 testing

Nature Reviews Clinical Oncology

Volumn 11, Issue 1, 2014, Pages 8-9

  Rakha, Emad A ^a   Ellis, Ian O ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; TUMOR MARKER; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN;

ALGORITHM; BREAST CANCER; CANCER PROGNOSIS; CHROMOSOME 17; DIAGNOSTIC ACCURACY; DISEASE MARKER; HEALTH CARE PERSONNEL; HUMAN; IN SITU HYBRIDIZATION; MEDICAL SOCIETY; NEEDLE BIOPSY; ONCOGENE NEU; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELIABILITY; SHORT SURVEY; STANDARDIZATION; UNITED STATES; BREAST NEOPLASMS; FEMALE; GENETIC SCREENING; GENETICS; ISOLATION AND PURIFICATION; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; WOMEN'S HEALTH;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; WOMEN'S HEALTH;

EID: 84891036635     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.230     Document Type: Short Survey

References (10)

1. Paik, S., Kim, C. & Wolmark, N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N. Engl. J. Med. 358, 1409-1411 (2008).
2. Perez, E. A. et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J. Clin. Oncol. 29, 3366-3373 (2011).
3. Wolff, A. C. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25, 118-145 (2007).
4. Wolff, A. C. et al. Recommendations for Human Epidermal Growth Factor Receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. http://dx.doi:10.1200/JCO.2013.50.9984 (2013).
5. Hammond, M. E. et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28, 2784-2795 (2010).
6. Middleton, L. P. et al. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. Arch. Pathol. Lab. Med. 133, 775-780 (2009).
7. Lee, A. H., Key, H. P., Bell, J. A., Hodi, Z. & Ellis, I. O. Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast. Histopathology 60, 880-884 (2012).
8. Hanna, W. M. et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod. Pathol. http://dx.doi:10.1038/modpathol.2013.103.
9. Starczynski, J. et al. HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. Am. J. Clin. Pathol. 137, 595-605 (2012).
10. Rakha, E. A. et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J. Clin. Oncol. 26, 3153-3158 (2008).